tein-associated receptors. Unlike the other prostanoids, for which a single receptor has been identified, PGE 2 binds with similar affinity to four receptors: EP1, EP2, EP3, and EP4 (9) . The EP3 receptor is unique in that multiple isoforms have been identified. All of the prostanoid receptors identified to date are highly conserved across species (the sequence homology between human and mouse receptors is in the range of 80-90%) (9) , and multiple isoforms of EP3 are found in all species examined to date. In the mouse, three isoforms of the EP3 receptor have been identified (10) . EP3 isoforms differ in the primary sequence of the cytoplasmic domain and, as a consequence, differ in their coupling efficiency with various G proteins. EP3 receptors have been shown to couple to G i , G s , and G q proteins (11, 12) . Therefore it is likely that physiological consequences of activation of the EP3 receptor may vary substantially depending on the cell type examined.
In addition to revealing the expression of the thromboxane TP and the prostacyclin IP receptors, RT-PCR analysis of RNA prepared from human platelets indicates that platelets express at least two EP receptors, including three of the six human EP3 isoforms and EP4 (10) . The expression of numerous EP receptors coupled to different second messenger systems provides an explanation for the often contradictory actions of PGE 2 in physiological responses. Generation of mice deficient in each of the EP receptors has provided a direct approach for identifying both the receptors through which PGE 2 activates various cells and the contribution of these pathways to physiological responses in the animal. In this report, using a series of mice deficient in EP, IP, and TP receptors, we identified the prostanoid receptors and the mechanism through which PGE 2 regulates platelet physiology in vitro and in vivo. Taken together, these studies support a model in which local production of PGE 2 during inflammatory responses dramatically enhances platelet aggregation by opposing increases in cAMP, such as those mediated by prostacyclin, and hence increasing the sensitivity of platelets to aggregating agents.
Methods
Animal welfare. The use of experimental animals was in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill.
Mice. Generation of Ep2 -/- (13) , Ep3 -/- (14) , Ep4 -/- (15) , and Ip -/- (16) mice used in this study has been reported previously. The Ep1 null mutation was introduced into the DBA/1Lac background by targeted disruption of this gene using an embryonic stem cell line derived directly from the DBA/1Lac mouse strain. EP2-, EP3-, and IP-deficient mice were maintained in our animal facility on 129 background, EP1-deficient mice on DBA background, and EP4-deficient mice on mixed background. Eight-to twenty-week-old male and female mice were used for experiments, and wild-type littermate animals were used as controls.
Platelet aggregation. Whole blood was collected from the heart of mice under pentobarbital anesthesia into heparinized (10 U/ml) syringes, except when stated that blood was collected on 3.8% sodium citrate. Blood was pooled from four to seven animals and centrifuged at 100 g for 15 minutes, enabling separation of platelet-rich plasma (PRP). Platelet-poor plasma was obtained by centrifugation of the remaining blood at 2,000 g for 15 minutes. Aggregation tests were performed in an optical Chronolog aggregometer (Chrono-Log Corp., Havertown, Pennsylvania, USA), using a volume of 250 µl of PRP adjusted to 500,000 platelets per µl, with plateletpoor plasma as diluent. Platelet-poor plasma also served as a 100% reference for aggregation.
Determination of cytosolic [Ca 2+ ]. After collecting blood in 0.35% (wt/vol) sodium citrate, PRP was prepared and centrifuged at 500 g for 10 minutes. Platelets were resuspended in Ca 2+ -free Tyrode's buffer containing 0.35% (wt/vol) albumin. Washed platelets were incubated with Indo-1AM (2 µg ml -1 ) for 45 minutes at ambient temperature in the dark. After centrifugation, platelets were resuspended in Ca 2+ -free Tyrode's buffer, and 1 mM CaCl 2 was added before the experiment. Cytosolic calcium was measured using a Perkin-Elmer 650-40 fluorometer (Perkin-Elmer Corp., Norwalk, Connecticut, USA).
Measurement of adenylyl cyclase activity in platelets. Washed platelets (1.5 × 10 7 ml -1 ) were stimulated with 10 µM PGE 2 (dinoprostone; Cayman Chemical, Ann Arbor, Michigan, USA) or 7 nM PGI 2 (epoprostenol sodium salt; Cayman Chemical) at 37°C. These PGE 2 or PGI 2 concentrations were previously determined to yield values in the middle of the cAMP standard curve. The reaction was stopped by 1:5 (vol/vol) perchloric acid (20%) at 15 seconds. Samples were incubated for 20 minutes on ice and centrifuged at 2,000 g for 15 minutes at 4°C. A total of 10 M KOH was added, and precipitating KClO 4 was pelleted by centrifuging at 2,000 g for 15 minutes at 4°C. Perchloric acid was removed using a mix of tri-n-octylamine and 1,1,2-trichloro-trifluoroethane. The amount of cAMP in the supernatant was determined using an enzyme immunoassay kit and following the manufacturer's instructions (Amersham Pharmacia Biotech, Little Chalfont, United Kingdom).
Bleeding time measurement. The tails of restrained mice were placed under a heating lamp at controlled temperature (37°C). The tail was cut off at 1 cm from the tip, and emerging blood was blotted every 15 seconds without touching the wound. Bleeding time was measured until bleeding had ceased for 30 seconds (17) . In a second experiment, mice were placed in a restraining device and their tails were secured in a vertical position. A 3-to 5-mm segment of the tail was transected, and the remaining length was immersed into 37°C sterile isotonic saline. Bleeding time was measured from transection time until bleeding could no longer be detected.
Analysis of thrombus formation. Mice (20-25 g) were anesthetized with pentobarbital and the jugular veins exposed by a cervical incision. A strip of Parafilm (American National Can, Chicago, Illinois, USA) was slipped under the vein and 100% ethanol, 30 µl of arachidonic acid (free acid, 50 mg/ml in ethanol), or eicosatrienoic acid (Cayman Chemical) was applied to the vein. After 1 minute, the Parafilm was removed, the wound was closed, and the mice were allowed to recover from anesthesia. After 3 hours, the vein was exposed again, and the presence of a thrombus was determined under magnification. The persistence of blood flow was examined by cutting the proximal end of the vein just upstream of the ligation of the jugular confluent. Thrombosis was scored from 0 to 4 as proposed previously (18) .
Results
Although PGE 2 (10 -7 to 10 -3 M) alone has no effect on platelet aggregation ex vivo, this lipid mediator can stimulate or inhibit platelet aggregation triggered by other agonists, including collagen, ADP, and thromboxane and its analogue U46619. The particular effect of PGE 2 on platelet aggregation is determined primarily by its local concentration. Thus, as shown in Figure 1 and consistent with previous observations (19) (20) (21) , PGE 2 added at concentrations below 10 -5 M does not induce platelet aggregation but enhances aggregation induced by U46619, ADP, or collagen. Conversely, at concentrations greater than 10 -4 M, PGE 2 markedly inhibits the ability of these agonists to promote aggregation. PGE 2 mediates its biologic actions by binding to one of four different cell-surface receptors, termed EP1, EP2, EP3, and EP4 (9, 22, 23) . This raises the possibility that the two opposing actions of PGE 2 on platelet function might be mediated by different EP receptors. To determine whether this is the case, we examined the effects of low (10 -7 M) and high (10 -4 M) concentrations of PGE 2 on the function of platelets that were deficient in each of the four EP receptors.
As shown in Figure 2 , low concentration of PGE 2 enhanced U46619-induced aggregation of platelets from EP1-, EP2-, or EP4-deficient mice, and the proaggregatory action of PGE 2 on these platelets was essentially identical to that observed with wild-type platelets. In contrast, 10 -7 M PGE 2 did not enhance aggregation of platelets obtained from EP3-deficient mice. This indicates that the ability of PGE 2 to augment platelet aggregation is mediated primarily by stimulation of the EP3 receptor.
We then examined the mechanism by which high concentrations of PGE 2 inhibit platelet aggregation. To determine the role of the EP receptors in the inhibitory effect of PGE 2 at higher concentrations (10 -4 M), we again isolated platelets from mice deficient in each of the four PGE 2 receptors and strain-matched control animals. As shown in Figure 3 , 6 × 10 -4 M PGE 2 completely inhibited the ability of ADP to induce platelet aggregation of wild-type platelets ( Figure 3a ) and of platelets deficient in each of the EP receptors ( Figure 3d ).
As already discussed here, activation of the IP receptor has long been recognized to exert a strong inhibito-
Figure 1
The dual effect of PGE 2 on platelet aggregation. (a) Wild-type platelets are exposed to a low concentration of U46619 (1 µM), collagen (0.75 µg/ml), or ADP (100 nM) in the absence or presence of 10 -7 M PGE 2 . At these low levels of stimulation, these agonists do not induce aggregation, except in the presence of PGE 2 . (b) Higher PGE 2 concentrations inhibit the full aggregation induced by 5 µM U46619, 1.25 µg/ml collagen, or 5 µM ADP. Scale bars represent 1 minute. These experiments were repeated three times, and representative traces are shown. The mean of the maximal aggregation was calculated for samples treated with PGE 2 and the aggregating agent and for samples treated with the aggregating agent alone. In all cases, the maximal aggregation was significantly higher in the PGE 2 -treated samples (P < 0.01; unpaired t test).
Figure 2
The PGE 2 -induced potentiation of aggregation is mediated by the EP3 receptor. Comparison of PGE 2 (10 -7 M) mediated potentiation of aggregation induced by U46619 (1 µM; indicated by the letter "U") treatment of wild-type platelets (WT) and platelets deficient for each of the prostaglandin receptors. PGE 2 -induced potentiation is observed in all the samples, with the exception of those lacking the EP3 receptor. Bars = 1 minute. Similar results were obtained on three consecutive experiments, and representative traces are shown. The maximal aggregation induced by PGE 2 treatment of EP receptor-deficient platelets in each experiment was calculated, and the mean was compared with similarly treated wild-type platelets. A significant difference (unpaired t test; P < 0.01) was observed only on comparison of the EP3-deficient platelet with wild-type controls.
ry effect on platelet aggregation (24) . We therefore carried out experiments to determine whether this receptor might contribute to PGE 2 -mediated inhibition. As depicted in Figure 3 , 10 -4 M PGE 2 alone induced aggregation in IP-deficient platelets, unmasking for the first time a third activity of PGE 2 on platelets (Figure 3a) . Moreover, the addition of ADP further stimulated this aggregation response.
Given that the inhibitory effect of prostacyclin in platelets might be countered by thromboxane, among other mediators, we considered the possibility that high concentrations (>10 -4 M) of PGE 2 might indirectly or directly activate the receptor for thromboxane (TP). To prevent thromboxane production, platelets were treated with the COX-inhibitor indomethacin. Under these conditions, 10 -4 M PGE 2 alone still induced aggregation (data not shown). This result suggests that the response of platelets to PGE 2 results from a direct and nonspecific activation of the TP receptor. To address this question, we generated mice with combined deficiency of both the IP and TP receptors. As shown in Figure 3b , in contrast to platelets that are deficient in IP receptors alone, PGE 2 failed to induce aggregation of IP-deficient platelets that also lacked the TP receptor. This provides direct evidence that at concentrations above 10 -4 M, PGE 2 can activate the TP receptor, and in the absence of the IP receptor this activation leads to platelet aggregation. The observation that PGE 2 alone was sufficient to induce aggregation only in the absence of the IP receptor suggests that the IP receptor mediates the inhibitory effect of high concentrations of PGE 2 on aggregation of wild-type platelets. To examine this possibility, we tested the ability of PGE 2 to inhibit ADP-induced aggregation of platelets deficient in both IP and TP receptors. In this case, 10 -4 M PGE 2 did not inhibit aggregation in response to ADP (Figure 3c) . Taken together, these data indicate that PGE 2 mediates its inhibitory effects on platelet aggregation through activation of the IP receptor.
We next examined the signaling mechanism used by PGE 2 to mediate these various effects on platelet physiology. Among the EP receptors, the EP3 receptor is unique in that multiple EP3 isoforms are generated by alternative splicing, and these isoforms couple to different G proteins (11, 12, 25) . These include G q , which drives mobilization of internal calcium stores (26), and G s or G i , which regulates intracellular levels of cAMP. We first determined whether treatment of platelets with PGE 2 alters intracellular calcium levels (Figure 4a ). Exposure of wild-type platelets to concentrations of PGE 2 from 10 -5 to 10 -7 M had no effect on intracellular calcium levels, whereas subsequent stimulation of these same platelets with U46619 induced a brisk calcium signal. In contrast, 10 -4 M PGE 2 increased calcium levels in IP-deficient platelets under the same experimental condition. However, this calcium signal was not observed in platelets deficient for both IP and TP receptors that were exposed to 10 -4 M PGE 2 . These data suggest that PGE 2 -induced calcium signaling in IP-deficient platelets is due to activation of the thromboxane receptor.
Previous studies have suggested that the intracellular level of cAMP in platelets plays a key role in determining their propensity for aggregation (27) . For example, inhibition of platelet aggregation by G s -coupled receptors such as the IP receptor is associated with increased intracellular cAMP levels (20) . Thus, we reasoned that if the inhibitory actions of higher concentrations of PGE 2 are mediated by the activation of the IP receptor, they should be associated with stimulation of intracellular cAMP. We therefore determined whether, similarly to prostacyclin, PGE 2 modifies platelet aggregation by altering cAMP levels. As seen in Figure 4b , and consistent with the results already described here, loss of the EP1, EP2, or EP4 receptor did not alter intracellular cAMP levels when compared with strain-and agematched controls. In contrast, EP3-deficient platelets exposed to 5 × 10 -5 M PGE 2 elicited a marked elevation of intracellular cAMP, and IP-deficient platelets failed to increase intracellular cAMP in response to PGE 2 or to prostacyclin. These results support a model in which PGE 2 alters platelet function through inhibition of
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The adenylate cyclase activity, and not through a direct mobilization of intracellular calcium. We next determined whether PGE 2 stimulation of the EP3 receptor could inhibit cAMP levels induced by agents in addition to prostacyclin. Platelets express the adenosine A 2a receptor, and activation of this G s coupled receptor has been shown to be responsible for adenosine-mediated increases in cAMP levels (28) . As shown in Figure 4 (inset), PGE 2 treatment decreased cAMP levels in platelets pretreated with adenosine in a dose-dependent manner. We suggest that the concentration of PGE 2 in the local environment modifies the intracellular level of cAMP, which in turn determines the response of the platelets to aggregating agents. Current literature suggests that the intracellular concentration of cAMP determines the extent of PKA activation, which is one pathway for regulating the availability of cytosolic calcium and phosphorylation of myosin (29) (30) (31) (32) (Figure 5a ). We next sought to determine whether the role of the EP3 receptor in modifying the response of platelets could be observed in vivo. We first examined the effect of loss of EP3 on bleeding time. Using two different protocols, we found no difference in the bleeding time between wild-type and EP3-deficient mice when measured by section of 1 cm of the tail (7.09 ± 4.09 minutes [n = 7] vs. 8.17 ± 1.44 minutes [n = 10]) or when measured by section of 3 mm of the tail immersed in saline (70 ± 18 seconds [n = 5] vs. 84 ± 19 seconds [n = 5]). We reasoned that the lack of any apparent role for EP3 receptors in primary hemostasis might reflect low levels of PGE 2 in these conditions. Furthermore, we suggest that the ability of the EP3 receptor to modulate platelet function might be more prominent in situations such as in inflammatory lesions or conditions in which PGE 2 production is stimulated. We further reasoned that PGE 2 -mediated modulation of platelet function might be particularly important in veins, given that after exposure to arachidonic acid, veins produce PGE 2 in excess of PGI 2 (33) . To mimic such conditions, we induced thrombosis by application of arachidonic acid to the periadventitial region of the vein. Within 3 hours in wildtype mice, periadventitial delivery of arachidonic acid caused significant intravascular clot formation without major alteration of blood flow ( Figure 5, b and c) . In this model, thrombus formation results from stimulation of the COX pathways. The inability of eicosatrienoic acid, a 20-carbon lipid with a chemical structure very similar to arachidonic acid, to induce thrombosis suggests that thrombus formation in this model depends on formation of metabolites of arachidonic acid (data not shown). Also, thrombus formation could be blocked by indomethacin treatment, which suggests that arachidonic acid induces thrombosis through the production of prostanoids (data not shown). To further characterize this model, we examined thrombus formation in mice lacking the TP and
The IP receptors: no thrombi were observed in these animals after periadventitial delivery of arachidonic acid. Thrombus formation was enhanced in IP-deficient mice, leading to total obstruction and interruption of vascular flow. In contrast, thrombus formation was almost completely abolished in EP3-deficient mice. The absence of thrombosis in the EP3-deficient mice suggests that PGE 2 produced during inflammatory processes may enhance thrombosis by activating the EP3 receptor, thereby opposing prostacyclin-mediated increases in cAMP. In this model, the opposing effects of PGE 2 and PGI 2 might modulate the amplitude of the platelet response to proaggregatory agents, such as thromboxane and ADP (Figure 5c ).
Discussion
Using a series of mice deficient in prostanoid receptors, we show that the reported ability of PGE 2 to inhibit platelet activation does not result from activation of the G s -coupled EP4 or EP2 receptors. In fact, this activity can be attributed to activation of the prostacyclin receptor at high PGE 2 concentrations. In contrast, the ability of PGE 2 to potentiate platelet activation is mediated by activation of a PGE 2 receptor, the EP3 receptor. In addition, we show that PGE 2 is unable to induce aggregation alone and potentiates platelet activation induced by other agonists through regulation of intracellular cAMP levels. Although EP3-deficient mice do not display increased bleeding times in a venous model of arachidonic acid induced inflammation, we show that mice deficient in the EP3 receptor are resistant to thrombus formation.
The ability of agents that increase intracellular cAMP levels to inhibit platelet aggregation has long been recognized. The ability of PGE 2 and PGE 1 to inhibit platelet aggregation was believed to be due to activation of adenylate cyclase by these agents (19, 20) . Cloning and characterization of the PGE 2 receptors revealed three receptors capable of coupling to G s proteins: the EP2 receptor, the EP4 receptor, and some isoforms of the EP3 receptor (9) . This raised the possibility that these receptors might mediate the inhibitory action of PGE 2 . We show here, however, that in mouse platelets the inhibitory actions of PGE 2 are not affected by loss of the EP2, EP4, or EP3 receptor. Only loss of the IP receptor affected the ability of PGE 2 to inhibit platelet aggregation. To observe this difference, it was first necessary to generate platelets that were deficient in both the IP-and the TP-receptors, owing to the unexpected observation that high concentrations of PGE 2 are able to activate the TP receptor. In the absence of inhibitory IP-mediated signals, PGE 2 activation of the TP receptor leads to platelet aggregation. Based on the concentration needed for the PGE 2 -induced inhibitory effect (>10 -4 M), this pathway is not expected to contribute extensively to the regulation of platelet activation in vivo.
The physiologically relevant action of PGE 2 on platelet aggregation is likely to be related to the ability of low concentrations of PGE 2 (<10 -6 M) to increase markedly the sensitivity of platelets to aggregating agents. We show here that this action is dependent on expression of the EP3 receptor. As already discussed
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The (20, 35, 36) . In summary, PGE 2 can now be added to a growing number of mediators, including epinephrine and ADP, which modulate platelet aggregation by regulating intracellular levels of cAMP. It is likely that these pathways provide a means of linking this homeostatic response to other ongoing physiological responses in the organism. Pharmacological studies suggest that the response of human and mouse platelets to prostanoids are very similar. For example, in platelets of both species, prostacyclin is a potent inhibitor of platelet aggregation including the response to thromboxane. Similar to our results with mouse platelets, PGE 2 has been shown to enhance the response of human platelets to aggregating agents in vitro (19, 20, 37) . PCR analysis of RNA prepared from purified platelets indicates that human platelets express high levels of both EP3 and the G s -coupled EP4 receptors, leading to speculation that these receptors might mediate the opposing actions of PGE 2 (10) . Although our studies do not identify a role for the EP4 receptor in cAMP production, they clearly show that activation of the EP3 receptor opposes the actions of the G s -coupled IP receptors in platelets. In both human and mouse platelets, the primary stimulus for increases in cAMP is likely to be through activation of IP. The ability of EP3 to oppose the protective functions of IP and enhance platelet aggregation should have a potent impact on thrombus formation in diseases.
While circulating levels of prostanoids are extremely low in healthy individuals (38) , the local concentration of PGE 2 can dramatically increase in inflammatory states. For example, the local production of PGE 2 was shown in vitro to increase more than 30-fold in aortoiliac occlusive disease (39) . It is, therefore, plausible that chronically inflamed vessels produce sufficient quantities of PGE 2 to activate EP3 receptors on platelets. In this environment, the intracellular events triggered by activation of the EP3 receptor may enhance platelet aggregation by opposing the effects of PGI 2 and enhancing the effects of primary aggregating agents such as ADP. EP3 receptor activation may therefore contribute to the thrombosis observed in pathological states such as vasculitis and atherosclerosis.
